BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Teva
Chubb
Accenture
Fuji
Harvard Business School
Medtronic
Covington
US Army

Generated: January 17, 2018

DrugPatentWatch Database Preview

Teva Pharm Company Profile

« Back to Dashboard

What is the competitive landscape for TEVA PHARM, and when can generic versions of TEVA PHARM drugs launch?

TEVA PHARM has two hundred and sixty-eight approved drugs.

There are thirty-one US patents protecting TEVA PHARM drugs and there have been two Paragraph IV challenges on TEVA PHARM drugs in the past three years. There are thirty-four tentative approvals on TEVA PHARM drugs.

There are four hundred and nineteen patent family members on TEVA PHARM drugs in thirty-eight countries and three hundred and ninety-three supplementary protection certificates in thirteen countries.

Summary for Teva Pharm
International Patents:419
US Patents:31
Tradenames:223
Ingredients:216
NDAs:268

Drugs and US Patents for Teva Pharm

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms CEFAZOLIN SODIUM cefazolin sodium INJECTABLE;INJECTION 063016-002 Mar 14, 1989 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharm ARMONAIR RESPICLICK fluticasone propionate POWDER;INHALATION 208798-002 Jan 27, 2017 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-003 Jan 28, 2014 AP RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms VORICONAZOLE voriconazole TABLET;ORAL 091658-001 Apr 6, 2012 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharm AIRDUO RESPICLICK fluticasone propionate; salmeterol xinafoate POWDER;INHALATION 208799-003 Jan 27, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Teva Pharms GALANTAMINE HYDROBROMIDE galantamine hydrobromide TABLET;ORAL 077587-003 Jul 9, 2009 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms PREDNISOLONE prednisolone SYRUP;ORAL 040322-001 Jan 19, 2000 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharm ARMONAIR RESPICLICK fluticasone propionate POWDER;INHALATION 208798-001 Jan 27, 2017 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Teva Pharms OLANZAPINE AND FLUOXETINE HYDROCHLORIDE fluoxetine hydrochloride; olanzapine CAPSULE;ORAL 202074-001 Mar 25, 2013 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms MEMANTINE HYDROCHLORIDE memantine hydrochloride TABLET;ORAL 090052-002 Oct 25, 2011 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Teva Pharm

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-002 Feb 12, 2002 ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate FOR SOLUTION;SUBCUTANEOUS 020622-001 Dec 20, 1996 ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-002 Feb 12, 2002 ➤ Subscribe ➤ Subscribe
Teva Pharm AIRDUO RESPICLICK fluticasone propionate; salmeterol xinafoate POWDER;INHALATION 208799-001 Jan 27, 2017 ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-002 Feb 12, 2002 ➤ Subscribe ➤ Subscribe
Teva Pharm ARMONAIR RESPICLICK fluticasone propionate POWDER;INHALATION 208798-001 Jan 27, 2017 ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate FOR SOLUTION;SUBCUTANEOUS 020622-001 Dec 20, 1996 ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate FOR SOLUTION;SUBCUTANEOUS 020622-001 Dec 20, 1996 ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate FOR SOLUTION;SUBCUTANEOUS 020622-001 Dec 20, 1996 ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate FOR SOLUTION;SUBCUTANEOUS 020622-001 Dec 20, 1996 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for TEVA PHARM drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe for Injection 3.5 mg/vial ➤ Subscribe 10/26/2016
➤ Subscribe Delayed-release Tablets 20 mg ➤ Subscribe 6/3/2015
➤ Subscribe Injection 40 mg/mL, 1 mL pre-filled syringe ➤ Subscribe 2/26/2014
➤ Subscribe Injection 40 mg/mL, 1 mL pre-filled syringe ➤ Subscribe 1/29/2014
➤ Subscribe Extended-release Capsule 15 mg and 30 mg ➤ Subscribe 8/11/2008
Premature patent expirations for TEVA PHARM

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
➤ Subscribe ➤ Subscribe

Non-Orange Book US Patents for Teva Pharm

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,877,245 Modified release dosage forms of skeletal muscle relaxants ➤ Subscribe
9,808,587 Dose counter for inhaler having an anti-reverse rotation actuator ➤ Subscribe
6,655,381 Pre-metered dose magazine for breath-actuated dry powder inhaler ➤ Subscribe
9,526,850 Dose counters for inhalers, inhalers and methods of assembly thereof ➤ Subscribe
9,463,289 Dose counters for inhalers, inhalers and methods of assembly thereof ➤ Subscribe
9,108,010 Dose counters for inhalers, inhalers and methods of assembly thereof ➤ Subscribe
9,174,013 Dose counters for inhalers, inhalers and methods of assembly thereof ➤ Subscribe
9,526,851 Dose counters for inhalers, inhalers and methods of assembly thereof ➤ Subscribe
6,613,900 Cephalotaxane derivatives and process for their preparation ➤ Subscribe
9,533,111 Dose counters for inhalers, inhalers and methods of assembly thereof ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Teva Pharm Drugs

Supplementary Protection Certificates for Teva Pharm Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
11/016 Ireland ➤ Subscribe PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105
C0004 Belgium ➤ Subscribe PRODUCT NAME: ESTRADIOL, HEMIHYDRATE, NORETHISTERONE, ACETATE; NAT. REGISTRATION NO/DATE: NL 23753 19981210; FIRST REGISTRATION: SE - 14 007 19980306
3 5021-2015 Slovakia ➤ Subscribe PRODUCT NAME: EMTRICITABIN/RILPIVIRINHYDROCHLORID/TENOFOVIRDIZOPROXILFUMARAT; REGISTRATION NO/DATE: EU/1/11/737/001 - EU/1/11/737/002 20111128
C/GB97/086 United Kingdom ➤ Subscribe PRODUCT NAME: QUETIAPINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY-ACCEPTABLE SALT; REGISTERED: UK 12619/0112 19970731; UK 12619/0113 19970731; UK 12619/0114 19970731
C/GB04/003 United Kingdom ➤ Subscribe PRODUCT NAME: PARICALCITOL; REGISTERED: ES SPAIN 64.974 20020809; UK PL 00037/0403 20030721
90049-3 Sweden ➤ Subscribe PRODUCT NAME: KLINDAMYCIN (SOM KLINDAMYCINFOSFAT) OCH TRETINOIN; NAT. REG. NO/DATE: MTNR 46193 20130503; FIRST REG.: IR PA1332/043/001 20130322
C0008 Belgium ➤ Subscribe PRODUCT NAME: FOSPHENYTOINUM DINATRICUM; REGISTRATION NO/DATE: 19 IS 102 F12 19980901; FIRST REGISTRATION: GB PL00019/1057 19980204
16/014 Ireland ➤ Subscribe PRODUCT NAME: TENOFOVIR ALAFENAMIDE OR A SALT OR SOLVATE THEREOF, IN PARTICULAR TENOFOVIR ALAFENAMIDE FUMARATE; REGISTRATION NO/DATE: EU/1/15/1061/001-EU/1/15/1061/002 20151119
C0025 Belgium ➤ Subscribe PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215
00445 Netherlands ➤ Subscribe PRODUCT NAME: VALSARTAN, AMLODIPINE EN HYDROCHLOORTHIAZIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/09/569/001-060 20091016
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
Mallinckrodt
Daiichi Sankyo
AstraZeneca
Citi
UBS
Argus Health
Medtronic
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot